Franklin Resources Inc. Grows Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Franklin Resources Inc. boosted its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 1.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,776,880 shares of the biopharmaceutical company’s stock after buying an additional 23,594 shares during the quarter. Franklin Resources Inc.’s holdings in Intra-Cellular Therapies were worth $148,405,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its holdings in shares of Intra-Cellular Therapies by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock worth $1,878,000 after buying an additional 2,157 shares during the period. Barclays PLC increased its stake in Intra-Cellular Therapies by 282.0% in the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock worth $2,521,000 after purchasing an additional 25,435 shares during the period. Oak Ridge Investments LLC lifted its position in shares of Intra-Cellular Therapies by 74.1% during the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock worth $1,656,000 after purchasing an additional 8,440 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of Intra-Cellular Therapies by 3.3% in the third quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company’s stock worth $43,735,000 after purchasing an additional 18,865 shares during the last quarter. Finally, Merit Financial Group LLC bought a new stake in Intra-Cellular Therapies during the 4th quarter valued at about $206,000. Institutional investors own 92.33% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on ITCI. StockNews.com started coverage on shares of Intra-Cellular Therapies in a research report on Friday, March 28th. They set a “hold” rating on the stock. Baird R W cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Needham & Company LLC reissued a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Piper Sandler restated a “neutral” rating and issued a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Finally, Leerink Partnrs cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Eleven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Intra-Cellular Therapies has a consensus rating of “Hold” and an average target price of $106.23.

Intra-Cellular Therapies Trading Down 0.0 %

Shares of ITCI stock opened at $131.91 on Thursday. The company has a market cap of $14.05 billion, a PE ratio of -151.62 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 12-month low of $64.09 and a 12-month high of $131.98. The business’s fifty day simple moving average is $129.43 and its 200-day simple moving average is $100.82.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. On average, equities analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.